Please assess the completion status of the following clinical trial:

Trial Title: Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age~* Subject has a diagnosis of Idiopathic Thrombocytopenia Purpura (ITP) according to the American Society of Hematology (ASH) guidelines~* If subject is \> 60 years of age, subject has a written bone marrow biopsy report confirming the diagnosis of ITP~* Subject has received at least 1 prior therapy for ITP~* Subject has a platelet count \< 50,000 or their platelet count falls to \< 50,000 during or after a clinically-indicated taper or discontinuation of current ITP therapy~* Before any study-specific procedure, the appropriate written informed consent must be obtained~Exclusion Criteria:~* Subject has had a splenectomy for any reason~* Subject has an active malignancy~* Subject has a history of cancer, other than basal cell carcinoma or cervical carcinoma in situ, with treatment or active disease within 5 years~* Subject has a known history of bone marrow stem cell disorder~* Subject has participated in any study evaluating polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), AMG 531, or a thrombopoietic protein~* Subject is receiving other investigational agents or procedures~* Subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study~* Subject is pregnant or breast feeding~* Subject is not using adequate contraceptive precautions~* Subject has known sensitivity to any recombinant E. coli-derived product~* Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and does not have a legally acceptable representative~* Subject has any kind of disorder that compromises the ability of the subject to comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks.
- Standard of Care (Type: OTHER): Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).